BRPI0516516A - derivados de 5-arilamino-1h-piridina-2-ona 3,6-substituìda e compostos relacionados como inibidores de poli(adp-ribose) polimerase (parp) no tratamento de dano ou doença dos tecidos causad(o)a por necrose ou apoptose - Google Patents
derivados de 5-arilamino-1h-piridina-2-ona 3,6-substituìda e compostos relacionados como inibidores de poli(adp-ribose) polimerase (parp) no tratamento de dano ou doença dos tecidos causad(o)a por necrose ou apoptoseInfo
- Publication number
- BRPI0516516A BRPI0516516A BRPI0516516-4A BRPI0516516A BRPI0516516A BR PI0516516 A BRPI0516516 A BR PI0516516A BR PI0516516 A BRPI0516516 A BR PI0516516A BR PI0516516 A BRPI0516516 A BR PI0516516A
- Authority
- BR
- Brazil
- Prior art keywords
- parp
- adp
- ribose
- polymerase
- inhibitors
- Prior art date
Links
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title abstract 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title abstract 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000017074 necrotic cell death Effects 0.000 title 1
- 230000000451 tissue damage Effects 0.000 title 1
- 231100000827 tissue damage Toxicity 0.000 title 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000005418 aryl aryl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004050196A DE102004050196A1 (de) | 2004-10-15 | 2004-10-15 | Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| PCT/EP2005/010697 WO2006042638A1 (de) | 2004-10-15 | 2005-10-05 | 3,6-substituierte 5-arylamino-1h-pyidin-2-on derivative und verwandte verbindungen als poly(adp-ribose)polymerase (parp) inhibitoren zur behandlung von durch nekose oder apoptose verursachten gewebeschäden oder erkankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0516516A true BRPI0516516A (pt) | 2008-09-16 |
Family
ID=35414525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0516516-4A BRPI0516516A (pt) | 2004-10-15 | 2005-10-05 | derivados de 5-arilamino-1h-piridina-2-ona 3,6-substituìda e compostos relacionados como inibidores de poli(adp-ribose) polimerase (parp) no tratamento de dano ou doença dos tecidos causad(o)a por necrose ou apoptose |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7863280B2 (enExample) |
| EP (1) | EP1802578B1 (enExample) |
| JP (1) | JP4875623B2 (enExample) |
| KR (1) | KR20070063005A (enExample) |
| CN (1) | CN101035761B (enExample) |
| AT (1) | ATE393146T1 (enExample) |
| AU (1) | AU2005297570C1 (enExample) |
| BR (1) | BRPI0516516A (enExample) |
| CA (1) | CA2583565A1 (enExample) |
| DE (2) | DE102004050196A1 (enExample) |
| DK (1) | DK1802578T3 (enExample) |
| ES (1) | ES2304721T3 (enExample) |
| IL (1) | IL182093A (enExample) |
| MX (1) | MX2007003360A (enExample) |
| PT (1) | PT1802578E (enExample) |
| WO (1) | WO2006042638A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003284237A1 (en) * | 2002-10-16 | 2004-05-04 | Transport Systems, Inc. | Monorail sortation system |
| US7961081B2 (en) * | 2003-05-22 | 2011-06-14 | John Tomlienovic | Anti-theft system and method |
| CN101242822B (zh) | 2005-07-18 | 2011-08-24 | 彼帕科学公司 | 治疗卵巢癌的药物 |
| AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| JP2010502731A (ja) | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法 |
| WO2009012242A2 (en) * | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| KR20100102609A (ko) | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| WO2011141909A2 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| AU2016296905B2 (en) | 2015-07-23 | 2018-07-05 | Centre National De La Recherche Scientifique | Use of a combination of Dbait molecule and parp inhibitors to treat cancer |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3615026B1 (en) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| ES3008911T3 (en) | 2017-07-11 | 2025-03-25 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| JP7534218B2 (ja) | 2018-03-13 | 2024-08-14 | ヴァレリオ・セラピューティクス | がんの治療における獲得耐性に対抗するｄｂａｉｔ分子 |
| WO2020012357A1 (en) * | 2018-07-10 | 2020-01-16 | Integral Biosciences Pvt. Ltd. | Heterocyclic compounds and methods of use |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| JP7646643B2 (ja) * | 2019-10-04 | 2025-03-17 | アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・（インセルム） | 新規なピリジン－２（１ｈ）オン誘導体、その調製、及び疼痛を処置するためのその使用 |
| CA3159461A1 (en) | 2019-11-25 | 2021-06-03 | Iwao Ojima | Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer |
| US20230348401A1 (en) * | 2020-01-15 | 2023-11-02 | The Trustees Of Princeton University | Inhibitors of Glucose-6-phosphate Dehydrogenase and Uses Thereof |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL70169A0 (en) * | 1982-11-18 | 1984-02-29 | Sterling Drug Inc | 2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them |
| GB9121651D0 (en) * | 1991-10-11 | 1991-11-27 | Smithkline Beecham Plc | Chemical compounds |
| CA2153498A1 (en) * | 1993-11-10 | 1995-05-18 | Hidetsura Cho | Chroman derivative and medicinal use thereof |
| AU770600B2 (en) * | 1999-10-07 | 2004-02-26 | Amgen, Inc. | Triazine kinase inhibitors |
| EP1423120A4 (en) * | 2001-08-15 | 2005-12-28 | Icos Corp | 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
-
2004
- 2004-10-15 DE DE102004050196A patent/DE102004050196A1/de not_active Withdrawn
-
2005
- 2005-10-05 WO PCT/EP2005/010697 patent/WO2006042638A1/de not_active Ceased
- 2005-10-05 PT PT05788702T patent/PT1802578E/pt unknown
- 2005-10-05 AU AU2005297570A patent/AU2005297570C1/en not_active Ceased
- 2005-10-05 CN CN2005800338248A patent/CN101035761B/zh not_active Expired - Fee Related
- 2005-10-05 EP EP05788702A patent/EP1802578B1/de not_active Expired - Lifetime
- 2005-10-05 AT AT05788702T patent/ATE393146T1/de active
- 2005-10-05 JP JP2007536043A patent/JP4875623B2/ja not_active Expired - Fee Related
- 2005-10-05 BR BRPI0516516-4A patent/BRPI0516516A/pt not_active IP Right Cessation
- 2005-10-05 MX MX2007003360A patent/MX2007003360A/es active IP Right Grant
- 2005-10-05 DE DE502005003866T patent/DE502005003866D1/de not_active Expired - Lifetime
- 2005-10-05 ES ES05788702T patent/ES2304721T3/es not_active Expired - Lifetime
- 2005-10-05 DK DK05788702T patent/DK1802578T3/da active
- 2005-10-05 CA CA002583565A patent/CA2583565A1/en not_active Abandoned
- 2005-10-05 KR KR1020077008550A patent/KR20070063005A/ko not_active Abandoned
-
2007
- 2007-03-21 IL IL182093A patent/IL182093A/en not_active IP Right Cessation
- 2007-04-11 US US11/733,833 patent/US7863280B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1107088A1 (en) | 2008-03-28 |
| IL182093A0 (en) | 2007-07-24 |
| DE502005003866D1 (de) | 2008-06-05 |
| CN101035761B (zh) | 2010-06-02 |
| PT1802578E (pt) | 2008-07-07 |
| AU2005297570B2 (en) | 2011-06-16 |
| ATE393146T1 (de) | 2008-05-15 |
| DE102004050196A1 (de) | 2006-04-20 |
| US20070281948A1 (en) | 2007-12-06 |
| CA2583565A1 (en) | 2006-04-27 |
| IL182093A (en) | 2011-02-28 |
| ES2304721T3 (es) | 2008-10-16 |
| EP1802578A1 (de) | 2007-07-04 |
| AU2005297570C1 (en) | 2012-06-07 |
| KR20070063005A (ko) | 2007-06-18 |
| WO2006042638A1 (de) | 2006-04-27 |
| CN101035761A (zh) | 2007-09-12 |
| EP1802578B1 (de) | 2008-04-23 |
| MX2007003360A (es) | 2007-05-23 |
| AU2005297570A1 (en) | 2006-04-27 |
| JP2008516902A (ja) | 2008-05-22 |
| JP4875623B2 (ja) | 2012-02-15 |
| DK1802578T3 (da) | 2008-08-11 |
| US7863280B2 (en) | 2011-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL182093A0 (en) | 3,6-substituted 5-arylamino-1h-pyridine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis | |
| NO20076502L (no) | Pyrrolopyridiner nyttige som inhibitorer av proteinkinase | |
| NO20063028L (no) | 6-substituerte 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer | |
| NO20063129L (no) | Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer | |
| NO20062892L (no) | 7-fenylalkyl-substituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)-polymeraseinhibitorer | |
| NO20062894L (no) | 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer | |
| NO20070526L (no) | Kinazolindionderivater som parp-inhibitorer | |
| ATE540928T1 (de) | Isochinolinverbindungen und ihre medizinische verwendung | |
| WO2004087699A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
| WO2004087698A3 (en) | Thiazoles useful as inhibitors of protein kinases | |
| MA28076A1 (fr) | Derives de 2,4-di(hetero)-arylamino-pyrimidine comme inhibiteurs des kinases zap-70 et/ou syk | |
| NO20062726L (no) | Nye pyridazin-3(2H)-on derivater | |
| ATE454378T1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
| NO20053144L (no) | Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler. | |
| DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| NO20071521L (no) | Nye fenylaminopyrimidin derivater som hemmere av BCR-ABL kinase | |
| ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
| MY140291A (en) | Sulfoximine-substituted pyrimidines for use as cd and/or vegf inhibitors, the production thereof and their use as drugs | |
| NO20084516L (no) | Terfenylderivater for behandling av alzheimers sykdom | |
| WO2007143523A8 (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| NO20092035L (no) | Tiazolylforbindelser anvendbare som kinaseinhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2274 DE 05/08/2014. |